Lessons from regadenoson and low-level treadmill/regadenoson myocardial perfusion imaging: Initial clinical experience in 1263 patients

Autor: Deborah H Kwon, Richard C. Brunken, Ron Young, Elizabeth A. Lieber, Venu Menon, Wael A. Jaber, Penny L. Houghtaling, Manuel D. Cerqueira
Rok vydání: 2010
Předmět:
Zdroj: Journal of Nuclear Cardiology. 17:853-857
ISSN: 1532-6551
1071-3581
DOI: 10.1007/s12350-010-9229-z
Popis: Regadenoson is a pharmacologic stress agent, which was recently approved for stress myocardial perfusion imaging (MPI). Aside from the initial protocol-driven studies, clinical experience with this stress agent is limited. Furthermore, low-level treadmill testing in a large population with regadenoson has not previously been evaluated. We describe our experience in the first 6 months of routine inpatient and outpatient clinical use. Between 7/1/08 and 12/04/08, 1263 patients underwent regadenoson stress testing (596 with low-level treadmill, 667 supine). Past medical history, clinical symptoms during stress, and changes in systolic blood pressure were prospectively recorded. Low-level treadmill testing was well tolerated in our patient population. Shortness of breath, dizziness, palpitations, transient heart block, and nausea were less frequent when patients were able to exercise. In our population, 51% experienced a drop in systolic blood pressure greater than 10 mmHg, with 9% experiencing a decrease in more than 30 mmHg. This decrease in blood pressure was more common in patients who underwent low-level treadmill testing vs those that were supine (56% vs 47%, P-value
Databáze: OpenAIRE
Externí odkaz: